Obermannova, Radka <br/><br/>
High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  07 2019 
 - 107-113 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2019.05.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Capecitabine--therapeutic use<br/>Cetuximab--therapeutic use<br/>Cisplatin--therapeutic use<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Prevalence<br/>Prognosis<br/>Stomach Neoplasms--blood<br/>Treatment Outcome<br/>Vitamin D--blood<br/>Vitamin D Deficiency--epidemiology